Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
about
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosisA novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapyReporting performance of prognostic models in cancer: a review.Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.Critical review of prostate cancer predictive toolsHigh-risk prostate cancer in the United States, 1990-2007Cancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S): ability to predict cancer progression and decision-making regarding adjuvant therapy after radical prostatectomy.Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.The example of CaPSURE: lessons learned from a national disease registryThe CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohortCirculating microRNAs as potential new biomarkers for prostate cancer.Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome.Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer.Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancerDiabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer.Prognostic value of the CAPRA clinical prediction rule: a systematic review and meta-analysis.Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches.The status of surgery in the management of high-risk prostate cancer.Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy.Changes in prostate cancer grading: Including a new patient-centric grading system.Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort.Predictive value of the cancer of the prostate risk assessment score for recurrence-free survival after radical prostatectomy in Korea: a single-surgeon series.Prostate cancer risk assessment: choosing the sharpest tool in the shed.External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series.External validation of the cancer of the prostate risk assessment-s score in koreans undergoing radical prostatectomy.Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results.Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer.Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy.Do prostate cancer nomograms give accurate information when applied to European patients?Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
P2860
Q24645292-C3E67061-A81E-4412-BBBD-6E58D5411E84Q28543958-16D3AAF6-32F6-4426-B2FE-06BAEC4F2DFBQ33547696-630E2D0D-0D5E-4172-946D-1F6966876986Q33993472-21389B1A-D6B9-4755-96E5-4E764FD826FAQ34104562-1BA2E1CC-1528-4B7D-9DBB-53E92DE04940Q34168382-D2E06F7D-4A35-47F7-83C1-62BA054C2648Q34208260-1D9383BE-BBD3-4197-8206-87EE8216F4F7Q34288796-E921FC34-4755-45F4-922C-2BE324434351Q34996369-7D29A37C-6794-454A-96DE-DD1C147BEAA3Q35207309-440E1554-2FFE-4C5F-9AB2-89A6AE345024Q35909631-17CA60A5-E623-4A03-A6C4-6EC7BA701339Q36896160-F03C643B-5F92-4C01-BC51-19496E1B9FB3Q36898434-BE26EE07-F297-4023-9B53-35153F2FF202Q37025434-D287EBD4-0B55-4A34-AB80-37A6CD7C1E21Q37254919-90DBE7B0-405E-482E-A822-F9AD45C8427AQ37658406-D11A1B2C-8DB3-435C-9752-020F71D4B66FQ38033730-CA1C40E2-0D4C-41F8-A421-CB0F94D2F522Q38047420-E6B37383-F105-475F-88DA-78BAE5E66417Q38211115-9BF7BD76-0BD7-43DE-9E19-0BD38908B8C7Q38640155-453CA4B8-8229-4A65-8EB2-9AA47B26D596Q38680873-C620C4D3-F28C-429C-B33C-6DD1D1FFC80CQ39756478-B2460863-4109-49EC-8494-21D2A7E152B2Q39756982-CDAFFB45-D995-4C32-AD80-37D34B6341CFQ42415354-0ABA3853-577C-4C6C-AA5F-A4E0AFF4EECAQ42819061-6EEDAE39-E6A2-40B1-B68D-9C9F8BC2FACFQ43085949-1004B05C-E17A-49FD-A5BA-DBDC2BA79779Q43497230-5B00CD90-A33D-4F48-9FD7-E63AC8121264Q44759241-1436F805-347B-4B67-8EAD-2CB50D824B01Q48210693-62EE6549-2E44-4764-BB5B-FC198BCF3301Q49423656-DA73F8FC-7028-4BB0-A272-4EA317AFFF0EQ50675542-8F1043CA-FA18-46F6-ABA3-5F0FB5235D69Q51803327-BEF2135B-86E6-4890-B152-41E00E1C7EF4Q53393814-B944D272-7C1C-4E9F-9413-3279FCC43286
P2860
Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Validity of the CAPRA score to ...... nter survey of 1,296 patients.
@ast
Validity of the CAPRA score to ...... nter survey of 1,296 patients.
@en
Validity of the CAPRA score to ...... nter survey of 1,296 patients.
@nl
type
label
Validity of the CAPRA score to ...... nter survey of 1,296 patients.
@ast
Validity of the CAPRA score to ...... nter survey of 1,296 patients.
@en
Validity of the CAPRA score to ...... nter survey of 1,296 patients.
@nl
prefLabel
Validity of the CAPRA score to ...... nter survey of 1,296 patients.
@ast
Validity of the CAPRA score to ...... nter survey of 1,296 patients.
@en
Validity of the CAPRA score to ...... nter survey of 1,296 patients.
@nl
P2093
P1476
Validity of the CAPRA score to ...... nter survey of 1,296 patients.
@en
P2093
Bernd Hoschke
Dirk Fahlenkamp
Horst Vogler
Matthias May
Michael Siegsmund
Nina Knoll
Oliver Gralla
P304
1957-62; discussion 1962
P356
10.1016/J.JURO.2007.07.043
P407
P577
2007-09-17T00:00:00Z